C. R. Bard, Inc.: Company Profile and SWOT Analysis

Document Sample
C. R. Bard, Inc.: Company Profile and SWOT Analysis Powered By Docstoc
					C. R. Bard, Inc.

_________________________________________________________________________________



C. R. Bard, Inc.                                                            Financial Snapshot

                                                                            Operating Performance
Fast Facts
                                                                            The company reported revenues of US$2,720.20
Headquarters Address               730 Central Avenue, Murray Hill, 07974
                                                                            million during 2010, with a CAGR of 8.27% during
                                                                            2006–2010. Its revenue grew at an annual rate of
Telephone                          + 1 908 2778000
                                                                            7.31% over the previous fiscal year. In 2010, the
                                                                            company recorded an operating margin of 26.38%, as
Fax                                + 1 908 2778240                          against 26.49% in 2009.

Website                            www.crbard.com
                                                                            Revenue and Margins
Ticker Symbol, Stock Exchange      BCR, New York Stock Exchange

Number of Employees                11,700

Fiscal Year End                    December

Revenue (in US$ million)           2,720.20




SWOT Analysis

Strengths                          Weaknesses                               Return on Equity

Focused on R&D activities          Dependence on the US market              The company recorded a return on equity (ROE) of
                                                                            31.21% for 2010, as compared to its peers, Baxter
                                                                            International Inc. (Ticker: BAX), AngioDynamics, Inc.
Strong financial performance       Host of legal proceedings and lawsuits   (Ticker: ANGO) and Boston Scientific Corporation
                                                                            (Ticker: BSX), which recorded ROEs of 21.62%,
Wide product portfolio                                                      3.15% and -9.43% respectively. The company
                                                                            reported an operating margin of 26.38% in 2010.


                                                                            Return on Equity
Opportunities                      Threats

Changing demographics              Cost containment pressures

Growing prevalence of cancer       Increasing competition

                                   Tightening of the FDA’s regulatory
Growth of healthcare expenditure
                                   oversight

Reprocessing medical devices




                                                                            Liquidity Position

                                                                            The company reported a current ratio of 3.85 in 2010,
                                                                            as compared to its peers, Baxter International Inc.,
                                                                            AngioDynamics,      Inc.   and     Boston    Scientific
                                                                            Corporation, which recorded current ratios of 1.98,
                                                                            6.58 and 1.39 respectively. As of December 2010, the
                                                                            company recorded cash and short-term investments
                                                                            of worth US$641.40 million, against zero current debt.
                                                                            The company reported a debt to equity ratio of 0.60 in
                                                                            2010 as compared to its peers, Baxter International
                                                                            Inc., AngioDynamics, Inc. and Boston Scientific
                                                                            Corporation, which recorded debt to equity ratios of
                                                                            0.67, 0.02 and 0.48 respectively.




___________________________________________________________________________________________

C. R. Bard, Inc. - SWOT Profile                                                                                     Page 1
C. R. Bard, Inc.

_________________________________________________________________________________


TABLE OF CONTENTS

1     Business Analysis ................................................................................................................................... 5
    1.1       Company Overview ................................................................................................................................................5
    1.2       Business Description ..............................................................................................................................................5
    1.3       Major Products and Services .................................................................................................................................6
    1.4       Key Financial Performance Indicators ...................................................................................................................8
      1.4.1       Revenue and Operating Profit ...........................................................................................................................8
      1.4.2       Asset, Liabilities and Capex ...............................................................................................................................9
      1.4.3       Operational Efficiency ......................................................................................................................................10
      1.4.4       Solvency ..........................................................................................................................................................11
      1.4.5       Valuation ..........................................................................................................................................................12
    1.5       Competitive Benchmarking ..................................................................................................................................13
      1.5.1       Market Capitalization .......................................................................................................................................14
      1.5.2       Efficiency ..........................................................................................................................................................15
      1.5.3       Capital Expenditure ..........................................................................................................................................16
      1.5.4       Turnover – Inventory and Asset.......................................................................................................................17
      1.5.5       Liquidity ............................................................................................................................................................18
2     Mergers & Acquisitions and Partnerships ........................................................................................... 19
    2.1       M&A and Partnerships Strategy ...........................................................................................................................19
3     Recent Developments ........................................................................................................................... 21
4     SWOT Analysis ...................................................................................................................................... 22
  
				
DOCUMENT INFO
Description: This SWOT analysis and company profile is a crucial resource for industry executives and anyone looking to gain a better understanding of the company's business. ICD Research's "C. R. Bard, Inc.: Company Profile and SWOT Analysis" report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
BUY THIS DOCUMENT NOW PRICE: $99 100% MONEY BACK GUARANTEED
PARTNER ICD Research
With emphasis on Insight, Consultancy and Delivery, iCD Research is a full-service, online market research agency. iCD Research is able to take advantage of all of the efficiencies and benefits that the Internet brings to offer proven research methodologies with fast turnaround and accurate results. iCD Research specialises in qualitative research for large finance, media, retail and entertainment clients. Market leaders in online focus groups, iCD Research has unleashed the full scale of the Internet to run focus groups across the globe for its major institutional clients. Utilising its sister organisation, The iD Factor, iCD Research also delivers strong quantitative research, ranging from ongoing consumer confidence studies through to consumer surveys throughout Europe and Asia. With its roots firmly in research, iCD Research doesn’t limit itself to only utilising online methods as the philosophy at the company is to match the methodology to the respondent. Yet the scale and speed of online research give iCD Research a cutting edge that has lead to tremendous, triple-figure percentage growth over the past two years. iCD Research is headquartered in London, with operational offices in the US and Australia to ensure that it is offering an unparalleled 24 hour service to its clients.